MMV s Access & Product Management Strategy
|
|
- Lindsey Cannon
- 5 years ago
- Views:
Transcription
1 MMV s Access & Product Management Strategy Siem Reap, Cambodia February 2015 George Jagoe, EVP, Access & Product Mgmt Defeating Malaria Together
2 OUR MISSION to reduce the burden of malaria in disease-endemic countries by But Drugs the DISCOVERING, journey only ANTIMALARIAL become from molecule medicines DEVELOPING DRUGS to once medicine & administered FACILITATING is not DELIVERY a seamless to patients. one. of new, effective and affordable antimalarial drugs.
3 The road to patient impact PRODUCT DEVELOPMENT REGULATORY APPROVAL PRODUCT READINESS POLICY & FINANCING DISTRIBUTION & DELIVERY PATIENT UPTAKE But the There journey are from many molecule gaps in the to medicine road to patient is not a impact. seamless one.
4 PRODUCT DEVELOPMENT REGULATORY APPROVAL PRODUCT READINESS POLICY & FINANCING DISTRIBUTION & DELIVERY PATIENT UPTAKE Access and Product Management fills the gaps throughout the entire product lifecycle.
5 CASE STUDY INJECTABLE ARTESUNATE 1 PRODUCT DEVELOPMENT CLOSING THE THE ACCESS ACCESS GAP GAP REGULATORY APPROVAL PRODUCT READINESS POLICY & FINANCING DISTRIBUTION & DELIVERY PATIENT UPTAKE APM began a systematic analysis of the barriers to uptake and MMV and its partners CHAI and Malaria Consortium co-hosted malaria3-year stakeholders meeting in late secureda asevere $34 million, grant from UNITAID that2011. is: Injectable Artesunate, a newly WHO-recommended treatment Access Gaps forintroduction malariathe was moving slowly in terms of introduction, 1severe Supporting procurement and scale-up of Inj AS SUPPORT policy change trainingdirect financing mono-supplier concerns acceptance, and widescale use incountries African countries years in six high-burden African (with 4.7 two million Access works closely with its pharma vials distributed in theand firstguideline year) change. response after WHO prequalification partnersapm s and country stakeholders 1 Develop policy briefs and training materials (video, print). to minimize time-to-market for new Slow uptake was costing lives. of a second manufacturer of Inj AS 2 to Negotiating the entrance products ensure acceptability ofsevere malaria guidelines. 2 and Support revision of WHO s products for maximum patient impact 3MSF Spearhead accelerated adoption in200 Nigeria and DRC. estimated that approximately 000 additional 3 Introducing first-time WHO-prequalified artesunate suppositories after launch. 4lives Create a multi-partner to tap switched new monies could be saved eachconsortium year if countries for the pre-referral treatment of severe malaria andquinine supporttobroad rollout. from Injectable Artesunate.
6 Global use in 2014 of Injectable Artesunate (WHO-prequalified) 11.5M vials ordered from Guilin Pharma Prequalified Inj AS has been registered in and delivered to 20 African countries and 5 Asian countries. With 25 million artesunate vials ordered since WHO prequalification, This translates to a potential K children s lives saved (vs. if treated with quinine.) 6
7 Severe Malaria: Recapping the Partners and their roles PRODUCT DEVELOPMENT REGULATORY APPROVAL PRODUCT READINESS POLICY & FINANCING DISTRIBUTION & DELIVERY PATIENT UPTAKE
8 Severe Malaria: Recapping the Partners and their roles PRODUCT DEVELOPMENT REGULATORY APPROVAL PRODUCT READINESS POLICY & FINANCING DISTRIBUTION & DELIVERY PATIENT UPTAKE
9 Treatments for Uncomplicated Malaria
10 Eurartesim Sigma-Tau (with marketing support from Pierre Fabre) Cl Cl N Product category Therapeutic indication Artemisinin Combination Therapy (ACT) Dihydroartemisinin + piperaquine Treatment of uncomplicated P. falciparum malaria in adults, children and infants >5kg Dosing Once daily for 3 days 28 day PCR-corrected ACPR 94.7% % Efficacy 42 day PCR-corrected ACPR 91.5% % O O Once daily Key features O Good post-treatment protection O H H Communicating new evidence about Challenges demonstrated safety (e.g. Cochrane 2014) HO Eurartesim H was first introduced in First stringent approval EMA WHO N prequalified in 2015 Approvals in Asia (Cambodia, India), and Cambodia N in 2012, as part of the Africa (Burkina Faso, Ghana, Mozambique, Status N Nigeria, Tanzania, Zambia*) Submitted for WHO prequalification in 2012 country s participation in the Ongoing regulatory review in 2 African and 7 Asian countries N Global Fund-based Evaluation of use in pregnancy (IPTp Next Affordable N alternative) and MDA in dual infection settings milestone Evaluation as MDA tool in Southern Africa Medicines Facility for Malaria.
11 Pyramax Shin Poong, University of Iowa HO Cl O O O O O O H H O H Product category Therapeutic indication Artemisinin Combination Therapy (ACT) Pyronaridine + artesunate Treatment of acute, uncomplicated malaria infection caused by P. falciparum or by P. vivax in adults and children 20kg use in low transmission areas with evidence of artemisinin resistance Dosing Once daily for 3 days Efficacy Key feature 28 day PCR-corrected ACPR > 98% 42 day PCR-corrected ACPR 90% - 95% Under evaluation (WHO) as alternative ACT for use in artemisinin resistance containment. EMA label specifies use for (blood-stage) cure of both vivax and falciparum Pyramax has been evaluated in Cambodia as part of its Phase 2 and Phase 3 program Single lifetime dosage (between Challenges 2005 and Pediatric formulation 2008). still in regulatory review Geographical restrictions N Approved 2012 by EMA (article 58) WHO pre-qualification cross-reference (2012) OH Status It is currently the focus Approved of in an Asia (South efficacy Korea, Vietnam, Cambodia) and Africa (Burkina Faso, Côte d Ivoire, Chad) N HN EMA decision on repeat-dose safety (2Q 2015) study N in O Western Next Cambodia, an area of EMA D120 feedback on pediatric granules milestone submission (Q1 2015) N artemisinin-resistant malaria.
12 Coartem Dispersible Novartis Product category Therapeutic indication Artemisinin Combination Therapy (ACT) Artemether + lumefantrine Treatment of adults and children >5kg with uncomplicated P. falciparum infection (including mixed infection) Dosing Twice daily for 3 days O O The O most widely distributed WHOprequalified malaria medicine 28 day cure rate (PCR-corrected) 94% - 98% O Efficacy H H 42 day cure rate (PCR-corrected) 96% - 100% Only pediatric ACT designed O formulation with Stringent H Key feature Regulatory Approval specifically to meet the needs Food effect: must of be children. given with fat Challenges Taste masked (cherry flavor) and sweetened Cl HO N Cl Status distributed Cl since Approved 2008 SwissMedic; 2009 WHO-PQ Approved in 35 endemic countries >250 million pediatric treatments distributed Over 250 million courses of medicine
13 ASMQ* DNDi / Cipla Product category Therapeutic indication Artemisinin Combination Therapy (ACT) Artesunate + Mefloquine (FDC) Treatment of adults and children >5kg with uncomplicated P. falciparum Dosing Once daily for 3 days Status Widely used in SE Asia and Latin America New studies demonstrating efficacy and safety in African patients As a fixed-dose combination, ASMQ meets a critical role as an important ACT for use in the emergency response to drug resistance in the Greater Mekong region. * Incorporated into MMV portfolio in 2015 (post-launch) through collaborative transfer from DNDi.
14 ASAQ* Sanofi / DNDi Product category Therapeutic indication Artemisinin Combination Therapy (ACT) Artesunate + Amodiaquine (FDC) Treatment of adults and children >5kg with uncomplicated P. falciparum Dosing Once daily for 3 days Status Widely used in Central and West Africa publication of results from Phase IV active pharmacovigilance study in Ivory Coast. The second most widely used WHOprequalified ACT, with major uptake primarily in Central and West Africa. * Incorporated into MMV portfolio as part of Phase IV post-launch safety study in West Africa in collaboration with Sanofi
15 P. Vivax Malaria (1) Preparing for the introduction of single-dose radical cure (2) Tapping a living «laboratory» to understand community delivery of radical cure
16 Tafenoquine: Key considerations for launch planning PRODUCT DEVELOPMENT REGULATORY APPROVAL PRODUCT READINESS POLICY & FINANCING DISTRIBUTION & DELIVERY PATIENT UPTAKE Defeating Malaria Together
17 Opportunity for Tafenoquine (+ G6PD test) Tafenoquine responds to a real unmet medical need Favourable policy environment: WHO new guidance on P. vivax Radical cure recommended in all transmission settings G6PD testing before radical cure with existing tests or referral to higher levels WHO ERG recommendation on specific G6PD test Push for elimination 17
18 18 Country prioritization criteria
19 Prerequisites to accelerate tafenoquine impact in countries 1. Registration in key countries 2. Inclusion in treatment guidelines WHO and National 3. Appropriate and affordable package: G6PD test + TQ 4. Appropriate supply chain 5. Modified clinical practice
20 20
21 CCMP is an operational research study under programmatic conditions Purpose Partners Assess the impact of universal access to diagnosis and treatment on malaria incidence in different transmission settings Better define the malaria burden and epidemiological profile in mixed infection environments Understand and address the challenges with radical cure Principal investigators: NIMR, NVBDCP / Odisha Support: MMV, WHO Study area Timelines Odisha, India 8 blocks (control and intervention) in 4 districts with different transmission intensity Population of 900K
22 High endemic API 17 Forest, hilly Medium endemic API 5 Low endemic API 2 Hyper endemic API 30 Tribal
23 Access and Product Management is mission-critical. It ensures that the right medicine in the right dose at the right time under the right conditions and at the right price gets to the right patient
24 Access and Product Management is mission-critical. It ensures that the right medicine in the right dose at the right time under the right conditions and at the right price gets to the right patient
25 Access and Product Management is mission-critical. It ensures that the right medicine in the right dose at the right time under the right conditions and at the right price gets to the right patient
26 Access and Product Management is mission-critical. It ensures that the right medicine in the right dose at the right time under the right conditions and at the right price gets to the right patient
27 Access and Product Management is mission-critical. $ It ensures that the right medicine in the right dose at the right time under the right conditions and at the right price gets to the right patient
28 Access and Product Management is mission-critical. ACCESS SAVES LIVES! It ensures that the right medicine in the right dose at the right time under the right conditions and at the right price gets to the right patient
29 ACCESS SAVES LIVES!
30 ACCESS SAVES LIVES!
31 ACCESS SAVES LIVES!
32 ACCESS SAVES LIVES!
33 ACCESS SAVES LIVES!
34 ACCESS SAVES LIVES!
35 ACCESS SAVES LIVES!
36 ACCESS SAVES LIVES!
37 ACCESS SAVES LIVES!
IMPLEMENTING RISK MANAGEMENT PLANS IN AFRICA: THE ASAQ Winthrop RISK MANAGEMENT PLAN. François Bompart Access to Medicines - Sanofi
IMPLEMENTING RISK MANAGEMENT PLANS IN AFRICA: THE ASAQ Winthrop RISK MANAGEMENT PLAN François Bompart Access to Medicines - Sanofi Artesunate Amodiaquine Winthrop (ASAQ Winthrop ) Infant (
More informationJaderson Lima, MD On behalf of François Bompart, MD
Challenges and Successes of the FACT Project through Innovative Partnerships for the Development of Artesunate Combination Therapies for Malaria 5º. ENIFarMed São Paulo Brazil August 2011 Public-private
More informationFixed Dose ACTs for Malaria in India
Best Science for the Most Neglected From patient needs to implementation of new treatments Fixed Dose ACTs for Malaria in India Dr Neena Valecha National Institute of Malaria Research Neena Valecha Scientist
More informationACTs in East Africa REALITY CHECK. Nathan Mulure MD Novartis Pharma
ACTs in East Africa REALITY CHECK Nathan Mulure MD Novartis Pharma 1 Agenda Introduction and background Drug resistance to antimalarials Policy change Antimalarial market Challenges 2 Malaria Burden 34,000
More informationMalaria eradication: marching to the beat of the global drum
1 Malaria eradication: marching to the beat of the global drum vivax malaria, was added to WHO s List of Prequalified Medicinal Products in 2016.. This will facilitate its delivery to the very young the
More informationDriving access to medicine
Driving access to medicine An example from the Novartis Malaria Initiative Hans Rietveld Director, Market Access & Capacity Building Novartis Malaria Initiative Social Forum - Geneva February 20, 2015
More informationMekong Malaria Elimination
Mekong Malaria Elimination Hiromasa Okayasu Coordinator, MME March 2018 Global Malaria Programme Malaria is caused by Parasite (Plasmodium) 2 Distribution of Vectors Human malaria is transmitted only by
More informationAntimalarials in the WHO Essential Drugs List for Children Reviewer No.1
Antimalarials in the WHO Essential Drugs List for Children Reviewer No.1 Part I: Evaluation of the current list Proposed grouping from the March 2007 meeting 6.5.3 Antimalarial medicines 6.5.3.1 For curative
More informationAntimalarial drug resistance
Antimalarial drug resistance Md Mushfiqur Rahman*, Leonard Ortega**, R M Rastogi* and Krongthong Thimasarn* Abstract Antimalarial drug resistance is of great concern in the WHO South-East Asia (SEA) Region.
More informationCombination Anti-malarial Therapy and WHO Recommendations
Prakaykaew Charunwatthana 2, and Sasithon Pukrittayakamee 1,2 1 Associate Fellow of the Royal Institute, Academy of Science 2 Department of Clinical Tropical Medicine, Faculty of Tropical Medicine, Mahidol
More informationAPPENDIX 1 DATA COLLECTION AND DISSEMINATION STEPS
APPENDIX 1 DATA COLLECTION AND DISSEMINATION STEPS 97 Country/ area APPENDIX 2a DRUG REGIMENS SEA REGION, 2001 (dosage for adults) : P. falciparum Lab confirmed Treatment failure Severe malaria Pregnancy
More informationA New Class of Malaria Drugs: The Coartem Breakthrough from Novartis
A New Class of Malaria Drugs: The Coartem Breakthrough from Novartis and its Chinese Partners Hans Rietveld, Director, Global Access and Marketing, Malaria Initiative, Novartis Pharma AG Workshop on Access
More informationDihydroartemisinin/Piperaquine Application for Inclusion in the 17 th WHO Model List of Essential Medicines 15 November 2010
APPLICATION FOR INCLUSION OF DIHYDROARTEMISININ PLUS PIPERAQUINE (DHA/PPQ) FIXED DOSE COMBINATION TABLETS IN THE 17 th EDITION OF THE WHO MODEL LISTS OF ESSENTIAL MEDICINES Page 1 TABLE OF CONTENTS 1.
More informationSourcing of ARVs & HIV diagnostics. Procurement for Impact P4i
Sourcing of ARVs & HIV diagnostics Procurement for Impact P4i AMDS ANNUAL STAKEHOLDERS AND PARTNERS MEETING 29 September 2014 Global Fund: Procurement for Impact: P4i Our objective was straightforward:
More informationMalaria Initiative: Access
Novartis Social Business Malaria Initiative: Access Improving affordability and availability of medicines Over the past decade, the Novartis Malaria Initiative has pioneered the pharmaceutical response
More informationArtesunate Mefloquine (AsMq)
Artesunate Mefloquine (AsMq) Introduction AsMq in Rakhine in 1996 AsMq FDC compared to other ACTs AZG (MSF-Holland) malaria activities in Western Myanmar 9 townships 25 DoH clinics with AZG support (area
More informationEncouraging Partnership and Collaboration for Success in the Field of R&D for Global Health
Encouraging Partnership and Collaboration for Success in the Field of R&D for Global Health Fil Randazzo, Ph.D. Deputy Director Global Health Discovery & Translational Sciences EVERY PERSON DESERVES THE
More informationUNITAID. Dr Philippe Duneton Deputy Executive Director Copenhagen September 2012
UNITAID Dr Philippe Duneton Deputy Executive Director Copenhagen September 2012 Challenges Achievements WHO Prequalification UNITAID support for prequalification of medicines Since 2007 UNITAID support
More informationDiagnostic Procurement The Clinton Foundation HIV/AIDS Initiative
Diagnostic Procurement The Clinton Foundation HIV/AIDS Initiative 28 October 2008 Geneva 1 CHAI Work in Diagnostics - Context Diagnostic Test Agreements - In 2002 when CHAI was formed, the price of many
More information14th Stakeholders Meeting
14th Stakeholders Meeting Steady progress towards malaria elimination: Interventions for today and tomorrow Denpasar, Bali 11 12 October 2017 David Hughes, Novartis 12th October 2017 Defeating Malaria
More informationBefore the House Foreign Affairs Subcommittee on Africa, Global Health, and Human Rights. December 5, 2011
Written Testimony of Dr. Dennis Schmatz President of the USA Board of Medicines for Malaria Venture and Chair of MMV s Expert Scientific Advisory Committee Before the House Foreign Affairs Subcommittee
More informationNew medicines for vulnerable populations
New medicines for vulnerable populations 4 New medicines for vulnerable populations Developing medicines for children 1 TPP: Target Product Profile. 2 World Health Organization, World Malaria Report 2013
More informationThe role of market intelligence in access to anti-malarial medicines: funding, procurement, and policy
The role of market intelligence in access to anti-malarial medicines: funding, procurement, and policy Brenda Waning Boston University School of Medicine November 20, 2009 American Society of Tropical
More informationAboubacar Kampo Chief of Health UNICEF Nigeria
Aboubacar Kampo Chief of Health UNICEF Nigeria Many thanks to UNICEF colleagues in Supply Division-Copenhagen and NY for contributing to this presentation Thirty-five countries are responsible for 98%
More informationArtesunate-Mefloquine (ASMQ) Fixed-Dose Combination (FDC), an additional tool in the armamentarium to control malaria in Latin-America
Artesunate-Mefloquine (ASMQ) Fixed-Dose Combination (FDC), an additional tool in the armamentarium to control malaria in Latin-America 1 st of December 2011- Rio de Janeiro Meeting chaired by Dr. Jean
More informationStrategy to move from accelerated burden reduction to malaria elimination in the GMS by 2030
Strategy to move from accelerated burden reduction to malaria elimination in the GMS by 2030 Dr Walter M Kazadi Coordinator Regional Hub Emergency Response to Artemisinin Resistance Regional Hub GMS MMV
More informationWHO Consultation on universal access to core malaria interventions in high burden countries: main conclusions and recommendations
WHO Consultation on universal access to core malaria interventions in high burden countries: main conclusions and recommendations 12-15 February 2018 Salle XI, ILO Building, Geneva, Switzerland Country
More informationAPPLICATION FOR REVISION AND INCLUSION OF MALARIA MEDICINES IN WHO MODEL LIST OF ESSENTIAL MEDICINES
APPLICATION FOR REVISION AND INCLUSION OF MALARIA MEDICINES IN WHO MODEL LIST OF ESSENTIAL MEDICINES The objective of this application is to assure compatibility between the WHO Model list of essential
More informationInterpretation of the World Malaria Report Country Profile
Interpretation of the World Malaria Report Country Profile Acknowledgements This presentation was developed to help explain the components of the World Malaria Report Country Profile. The 2017 World Malaria
More informationNew Partnerships The Development of ASMQ - FDC
New Partnerships The Development of ASMQ - FDC Jean-René Kiechel Senior Product Manager DNDi January 2011 1 ACTs: World Health Organization Treatment Guidelines (2006) In order to fight resistance: 1.
More informationBox 1. Recommendations unchanged from the first edition of the Guidelines (2006)
Executive summary Executive Summary Malaria case management remains a vital component of the malaria control strategies. This entails early diagnosis and prompt treatment with effective antimalarial medicines.
More informationGlobal Fund: Malaria in Pregnancy Perspectives
Global Fund: Malaria in Pregnancy Perspectives Dr. Roopal Patel, Malaria Advisor Malaria in Pregnancy Working Group Annual Meeting Geneva, Switzerland September 18, 2017 Strengthening systems for health
More informationThe Global Accelerator for Paediatric Formulations (GAP-f) Ensuring children have accelerated access to optimal drug formulations
Slide 1 The Global Accelerator for Paediatric Formulations (GAP-f) Ensuring children have accelerated access to optimal drug formulations Sébastien Morin (International AIDS Society, Switzerland) 9 th
More informationCopyright by Population Services International and ACTwatch 2016.
Malaria markets in the Greater Mekong Sub-Region: 2015-2016 1 Copyright by Population Services International and ACTwatch 2016. Suggested Citation: Malaria Markets in the Greater Mekong Sub-Region: 2015-2016.
More informationPriority essential medicines: identifying products. Dr Suzanne Hill September 2010
Priority essential medicines: identifying products Dr Suzanne Hill September 2010 The problem looks like this Robertson, Forte, Trapsida & Hill. Bull WHO 2009 Robertson, Forte, Trapsida & Hill. Bull WHO
More informationGAVI s Financing for Pneumococcal Vaccines, including the Advance Market Commitment
GAVI s Financing for Pneumococcal Vaccines, including the Advance Market Commitment Tania Cernuschi Third Regional Pneumococcal Symposium, Istanbul, 13th - 14th February 2008 1 The GAVI Alliance Public-private
More informationLa terapia della malaria
Verona, 15 marzo 2018 La terapia della malaria Zeno Bisoffi Ritardo diagnostico e carica parassitaria Turista (Kenya), 50 a, febbre da 3 h Turista (G. Bissau), 36 a, febbre da 8 gg Ritardo diagnostico
More informationPOLICY BRIEF Review of Antimalarial Medicines Available to Treat P. falciparum in the Amazon Region
POLICY BRIEF Review of Antimalarial Medicines Available to Treat P. falciparum in the Amazon Region Background Malaria is a substantial public health threat in the Americas. In 2010, the Americas had approximately
More informationEvidence Review Group on MDA, MSAT and FSAT Malaria Policy Advisory Committee Geneva, Switzerland September 2015
Evidence Review Group on MDA, MSAT and FSAT Malaria Policy Advisory Committee Geneva, Switzerland 16-18 September 2015 Kevin Marsh Chairperson of the Evidence Review Group 1 Outline of the Presentation
More informationExpert Consultation on Seasonal Malaria Chemoprevention (SMC) and next-generation chemoprevention medicines
Expert Consultation on Seasonal Malaria Chemoprevention (SMC) and next-generation chemoprevention medicines 13 14 January 2016 Grange Holborn Hotel, London Meeting funded by UNITAID within the framework
More informationTesting for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale
Testing for G6PD deficiency for safe use of primaquine in radical cure of P. vivax and P. ovale Webinar presentation to support the dissemination of the policy brief Silvia Schwarte, WHO/GMP e-mail: schwartes@who.int
More informationPneumococcal Conjugate Vaccine: Current Supply & Demand Outlook. UNICEF Supply Division
Pneumococcal Conjugate Vaccine: Current Supply & Demand Outlook UNICEF Supply Division Update: October 2013 0 Pneumococcal Conjugate Vaccine (PCV) Supply & Demand Outlook October 2013 Update Key updates
More informationDisclosure Information
Malaria Medications Charlie Mosler, RPh, PharmD, CGP, FASCP Assistant Professor of Pharmacy Practice The University of Findlay College of Pharmacy Findlay, OH mosler@findlay.edu Disclosure Information
More informationMalaria Symposia Myanmar Medical Association. Dr Aung Thi National Malaria Control Program 04 March 2017
Malaria Symposia Myanmar Medical Association Dr Aung Thi National Malaria Control Program 04 March 2017 OUTLINE OF THE PRESENTATION Country profile Programmatic achievements Challenges Lessons learnt Way
More informationWHO Global Malaria Programme. February 2009
WHO Global Malaria Programme February 2009 Table of Contents 1. The world malaria situation 2. The critical role of WHO's Global Malaria Programme 3. Our programme of work explained 4. Situation analysis
More informationDeveloping a novel Group B Streptococcus (GBS) Vaccine. Patrick Tippoo
Developing a novel Group B Streptococcus (GBS) Vaccine Patrick Tippoo Presentation 1. Overview of Biovac 2. GBS Project Overview 3. African Significance Biovac Overview A Centre of Excellence rooted in
More informationGuidance on Matching Funds: Tuberculosis Finding the Missing People with TB
February 2017 Guidance on Matching Funds: Tuberculosis Finding the Missing People with TB 1. Background TB is the leading cause of death by infectious disease, killing 1.8 million people in 2015. Each
More informationHIV Viral Load Testing Market Analysis. September 2012 Laboratory Services Team Clinton Health Access Initiative
HIV Viral Load Testing Market Analysis September 2012 Laboratory Services Team Clinton Health Access Initiative Agenda Background on Viral Load Testing Growth of Global Viral Load Market Factors Impacting
More informationInnovation, Access and Use Department of Essential Medicines and Health Products WHO
MARKETS FOR QUALITY-ASSURED PRODUCTS Sarah Garner and Francisco Blanco Innovation, Access and Use Department of Essential Medicines and Health Products WHO 1 Objectives Indicate market needs for medicines
More informationDisease Narrative for Malaria and Areas for Intervention
Disease Narrative for Malaria and Areas for Intervention ADAPTED FROM CONTENT DEVELOPED FOR PRESENTATION TO UNITAID EXECUTIVE BOARD FOR ITS 23 MEETING (11/2015) Executive Summary In the past 15 years,
More informationSummary World Malaria Report 2010
Summary The summarizes information received from 106 malaria-endemic countries and other partners and updates the analyses presented in the 2009 Report. It highlights continued progress made towards meeting
More informationUNITAID investments to innovate and scale up access to HIV diagnostics
UNITAID investments to innovate and scale up access to HIV diagnostics WHO Annual meeting with Diagnostic Manufacturers and Stakeholders 10 March 2016 Smiljka de Lussigny (HIV Diagnostics Programme Manager,
More informationHIV DIAGNOSTIC TESTS IN LOW- AND MIDDLE-INCOME COUNTRIES: FORECASTS OF GLOBAL DEMAND FOR
HIV DIAGNOSTIC TESTS IN LOW- AND MIDDLE-INCOME COUNTRIES: FORECASTS OF GLOBAL DEMAND FOR 2015 2020 Presented by Vincent Habiyambere (WHO), Biyi Adesina (Avenir Health) and Meghan Wareham (CHAI) on behalf
More informationUpdate on Meningococcal A Vaccine Development and Introduction
Update on Meningococcal A Vaccine Development and Introduction WHO Product Development for Vaccines Advisory Committee Meeting (PD-VAC) @ Geneva, 7-9 September 2015 Dr Marie-Pierre Preziosi, WHO Initiative
More informationLessons to be learned from HIV, TB and Malaria
Lessons to be learned from HIV, TB and Malaria Informal Consultation of Member States and relevant partners on the global development and stewardship framework to combat antimicrobial resistance Stewardship
More informationThe pathway to better medicines for children
The pathway to better medicines for children As the World Health Organization counts down to 2015 and the Millennium Development Goal to reduce under five-year-old mortality by two-thirds, we reflect on
More informationMaternal, Newborn and Child Health: Global initiatives and priority products for MNCH Dr. Mark W. Young Senior Health Specialist, UNICEF-New York
Maternal, Newborn and Child Health: Global initiatives and priority products for MNCH Dr. Mark W. Young Senior Health Specialist, UNICEF-New York Copenhagen, Denmark 23 September 2013 Visit www.everywomaneverychild.org
More informationClinical Drug Trials
Clinical Drug Trials Drug resistance to chloroquine in P. falciparum was reported in India for the first time from Assam in 1973. Since then the foci of resistance have spread to many more states all over
More informationGlobal Report on Antimalarial Drug. and the Global Plan for Artemisinin Resistance Containment (GPARC)
Global Report on Antimalarial Drug Resistance and Drug Efficacy: 2-21 21 and the Global Plan for Artemisinin Resistance Containment (GPARC) MMV Stakeholders Meeting Dar es Salaam, Tanzania 2 June 211 Robert
More informationCOLD CHAIN EQUIPMENT OPTIMISATION PLATFORM (CCEOP)
COLD CHAIN EQUIPMENT OPTIMISATION PLATFORM (CCEOP) Sushila Maharjan Senior Manager, Innovative Finance International Conference on Sustainable Cooling World Bank Washington DC - 29 November 2018 Reach
More informationMalaria. Dr. Salim Abdulla, Director Ifakara Health Institute, Dar-es-salaam, Tanzania
Malaria Dr. Salim Abdulla, Director Ifakara Health Institute, Dar-es-salaam, Tanzania Despite 42% reduction since 2000, a child dies every minute in Africa from malaria 207 million malaria cases in 2012,
More informationFighting Harder and Smarter Against Malaria. Dr.Bernard Nahlen Deputy US Global Malaria Coordinator University of Georgia, February 23, 2010
Fighting Harder and Smarter Against Malaria Dr.Bernard Nahlen Deputy US Global Malaria Coordinator University of Georgia, February 23, 2010 Outline Burden of malaria Global support for rolling back malaria
More information38 Current Concepts in
38 Current Concepts in Management of Falciparum Malaria Abstract: Artemisinin based Combination Therapy (ACT) is the preferred agent to treat drug resistance uncomplicated Plasmodium Falciparum (PF) Malaria.
More informationFixed Dose Combination a Simplified Approach to Pediatric Antiretroviral Treatment
Fixed Dose Combination a Simplified Approach to Pediatric Antiretroviral Treatment Dr. David Pugatch Clinton Foundation Phnom Penh, Cambodia February, 2007 Lecture Goals To introduce and define fixed dose
More informationAccess update, registration & procurement strategies Barbara ROTH Pharmacist, TB supply - MSF
Treating Patient, Not Disease: People-Centered Approach 1-2 March, 2018, BISHKEK, KYRGYZSTAN Access update, registration & procurement strategies Barbara ROTH Pharmacist, TB supply - MSF EML Guidelines
More informationGlobal Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive
Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive DR. Nicholas Muraguri OGW, MD,MPH, MBA, PhD (c) Director, Global Plan Secretariat www.zero-hiv.org
More informationGLOBAL MALARIA DIAGNOSTIC AND ARTEMISININ TREATMENT COMMODITIES DEMAND FORECAST
POLICY BRIEF GLOBAL MALARIA DIAGNOSTIC AND ARTEMISININ TREATMENT COMMODITIES DEMAND FORECAST 2017 2021 May 11, 2018 2018 World Health Organization (Acting as the host organization for, and secretariat
More informationEighth intercountry meeting of national malaria programme managers from HANMAT and PIAM-Net countries
Summary report on the Eighth intercountry meeting of national malaria programme managers from HANMAT and PIAM-Net countries WHO-EM/MAL/384/E Islamabad, Pakistan 12 14 December 2016 Summary report on the
More informationEXECUTIVE BOARD MEETING STRATEGIC NARRATIVE FOR MALARIA AND AREAS FOR INTERVENTION
EXECUTIVE BOARD MEETING STRATEGIC NARRATIVE FOR MALARIA AND AREAS FOR INTERVENTION 23RD MEETING, NOVEMBER 2015 EXECUTIVE BOARD MEETING STRATEGIC NARRATIVE FOR MALARIA AND AREAS FOR INTERVENTION 23RD MEETING,
More informationBalancing investment in point of care diagnostics versus laboratory testing in low resource settings. June 28, 2011
Balancing investment in point of care diagnostics versus laboratory testing in low resource settings Workshop on TB and HIV Diagnostics Workshop on TB and HIV Diagnostics June 28, 2011 Complexity Delivery
More informationThe cardiotoxicity of antimalarials Report of the WHO Evidence Review Group Meeting on October 2016
The cardiotoxicity of antimalarials Report of the WHO Evidence Review Group Meeting on 13-14 October 2016 Malaria Policy Advisory Committee (MPAC) Meeting 22-24 March 2017, World Health Organization, Geneva,
More informationEnding Malaria in Nigeria: The WHO Agenda
Nigeria Institute of Medical Research 2016 World Malaria Day Lecture 27 April, 2016 Ending Malaria in Nigeria: The WHO Agenda Dr Tolu Arowolo Malaria Containment Programme, WHO, Nigeria arowolot@who.int
More informationIntroduction to PAHWP-EAC-LSHTM Workshop on Assessment of Clinical Performance of in-vitro Diagnostics
Introduction to PAHWP-EAC-LSHTM Workshop on Assessment of Clinical Performance of in-vitro Diagnostics Rosanna W Peeling Professor and Chair, Diagnostic Research Director, International Diagnostics Centre
More informationPresentation by Dr Philippe Douste-Blazy. Chair of UNITAID Special Representative of the UN SG for Innovative Financing for Development
Presentation by Dr Philippe Douste-Blazy Chair of UNITAID Special Representative of the UN SG for Innovative Financing for Development The Millennium Goals : Hope for Humanity 2000 UN Millennium Summit
More informationCall to Action To Accelerate Access to DR-TB Drugs: 2016 Update
Call to Action To Accelerate Access to DR-TB Drugs: 2016 Update June 3, 2016 On March 10 th, 2015, Médecins Sans Frontières (MSF), ACTION Global Health Advocacy Partnership, SWIFT Response Project, Treatment
More informationArtesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria (Review)
Artesunate plus pyronaridine for treating uncomplicated Plasmodium falciparum malaria (Review) Bukirwa H, Unnikrishnan B, Kramer CV, Sinclair D, Nair S, Tharyan P This is a reprint of a Cochrane review,
More informationCopenhagen, Denmark, September August Malaria
Regional Committee for Europe 64th session EUR/RC64/Inf.Doc./5 Copenhagen, Denmark, 15 18 September 2014 21 August 2014 140602 Provisional agenda item 3 ORIGINAL: ENGLISH Malaria Following the support
More informationDiagnostics product development projects
Page 0 Diagnostics product development projects Smiljka de Lussigny Technical Officer, HIV UNITAID Copenhagen, 23 September 2013 Page 1 1 2 3 About UNITAID HIV diagnostics market UNITAID s current investment
More informationUpdating the Guidelines for the Treatment of Malaria
Updating the Guidelines for the Treatment of Malaria Meeting of the Malaria Policy Advisory Committee Geneva, 13-15 March, 2013 Prof. Nick White Co-chair, Chemotherapy Technical Expert Group With thanks
More informationProcurement Strategy for Rotavirus and Pneumococcal Conjugate Vaccines. Supplier meeting UNICEF Supply Division 3-4 April 2008 Ann Ottosen
Procurement Strategy for Rotavirus and Pneumococcal Conjugate Vaccines Supplier meeting Supply Division 3-4 April 2008 Ann Ottosen Strategic decisions leading to procurement of Rotavirus and Pneumococcal
More informationRAPID DIAGNOSIS AND TREATMENT OF MDR-TB
RAPID DIAGNOSIS AND TREATMENT OF MDR-TB FORMING PARTNERSHIPS TO STRENGTHEN THE GLOBAL RESPONSE TO MDR-TB - WHERE IT MATTERS MOST I am delighted that this initiative will improve both the technology needed
More informationMATERNAL, NEWBORN, AND CHILD HEALTH
MATERNAL, NEWBORN, AND CHILD HEALTH SESSION OBJECTIVES Introduction to GHSC-PSM Maternal, Newborn, and Child Health (MNCH) strategy and priorities Defining MNCH commodities Overview of historical and current
More informationDihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria (Review)
Dihydroartemisinin-piperaquine for treating uncomplicated Plasmodium falciparum malaria (Review) Zani B, Gathu M, Donegan S, Olliaro PL, Sinclair D This is a reprint of a Cochrane review, prepared and
More informationBMGF MALARIA STRATEGY TO 2020
BMGF MALARIA STRATEGY TO 2020 Supporting the Drive to Elimination in Mesoamerica & Hispaniola Diana Measham, DrPH, MSc Lead Eliminate Initiative September 25, 2014 The world has three potential future
More informationManuscripts for the WHO Evidence Review Group for malaria in pregnancy (MiP-ERG), July 2015
Malaria Policy Advisory Committee Meeting 5 7 March 2015, Geneva, Switzerland Background document for Session 4 Manuscripts for the WHO Evidence Review Group for malaria in pregnancy (MiP-ERG), July 2015
More informationThe PATH Innovation Pipeline for Malaria
path malaria learning series The PATH Innovation Pipeline for Malaria Transformative tools and approaches for defeating malaria Making progress against malaria requires collaboration across borders, sectors,
More informationInvitation to Manufacturers 16 August 2017
Invitation to Manufacturers 16 August 2017 Manufacturers of Antiretroviral (HIV/AIDS), Antihepatitis B and C, Antituberculosis and Antimalarial medicines Are Invited to Submit An Expression of Interest
More informationAddressing Malaria in Pregnancy: A Comprehensive Approach to Maternal and Newborn Health Outcomes
Addressing Malaria in Pregnancy: A Comprehensive Approach to Maternal and Newborn Health Outcomes Malaria is a major public health crisis, especially in sub-saharan Africa, where 90% of all malaria-related
More informationThe Challenge of Malaria
The Challenge of Malaria Prof. Awa-Marie Coll-Seck Executive Director of RBM Partnership Donors Forum (co-organized by MMV & CRESIB) Barcelona, 15 March 2010 A DECADE OF ROLLING BACK MALARIA: WHERE ARE
More informationAnalysis of the demand for a malaria vaccine: outcome of a consultative study in eight countries
Briefing Document: National decision-making framework for malaria vaccines Analysis of the demand for a malaria vaccine: outcome of a consultative study in eight countries This is one of seven briefing
More informationGAIN Premix Facility, a Global Premix procurement solution. UNICEF Supplier meeting 3-4 th of October 2011
GAIN Premix Facility, a Global Premix procurement solution UNICEF Supplier meeting 3-4 th of October 2011 The GAIN Vision, Mission, Goal GAIN stands for the Global Alliance for Improved Nutrition Driven
More informationVisceral Leishmaniasis treatment access: The reality on the ground
Visceral Leishmaniasis treatment access: The reality on the ground Margriet den Boer KalaCORE Regional Coordinator, East Africa Symposium Innovation for Access to Treatment for Neglected Diseases ASTMH,
More informationWorld Health Organization Global Fund concept note development WHO POLICY BRIEF
World Health Organization 2014 All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization,
More informationAn innovative mechanism for scaling up access to medicines and diagnostics for HIV/AIDS, tuberculosis and malaria
UNITAID An innovative mechanism for scaling up access to medicines and diagnostics for HIV/AIDS, tuberculosis and malaria ECOSOC Annual Ministerial Review (Regional Ministerial Meeting on Financing Strategies
More informationStrengthening Laboratory Systems for HIV Differentiated Service Delivery
ADVANCING THE LABORATORY PROFESSION AND NETWORKS IN AFRICA Strengthening Laboratory Systems for HIV Differentiated Service Delivery Anafi Mataka African Society for Laboratory Medicine AIDS 2018 Outline
More informationChronic hepatitis C Building access into drug development: DNDi strategy
Chronic hepatitis C Building access into drug development: DNDi strategy July 2017 IAS Isabelle Andrieux-Meyer Head of HIV/HCV Clinical Programs Declaration of interests Isabelle Andrieux-Meyer from Drugs
More informationA Head-to-Head Comparison of Four Artemisinin-Based Combinations for Treating Uncomplicated Malaria in African Children: A Randomized Trial
A Head-to-Head Comparison of Four Artemisinin-Based Combinations for Treating Uncomplicated Malaria in African Children: A Randomized Trial The Four Artemisinin-Based Combinations (4ABC) Study Group* "
More informationMARKET UPDATE: ROUTINE VACCINE INTRODUCTIONS PCV HPV ROTA
UNICEF/UN074388/LeMoyne MARKET UPDATE: ROUTINE VACCINE INTRODUCTIONS PCV HPV ROTA Vaccine Industry Consultation October 2018 Pneumococcal Conjugate Vaccine (PCV) Background The AMC initiative has opened
More informationAgainst intervention No recommendation Strong Conditional Conditional Strong. For intervention. High Moderate Low Very low
Draft recommendation: Consider using MDA as an additional tool for the elimination of malaria in low prevalence island or nonisland settings where the risk of imported malaria is low Balance of desirable
More informationProcedure for the expedited review of imported prequalified vaccines with view to granting a marketing authorization
Procedure for the expedited review of imported prequalified vaccines with view to granting a marketing authorization Prequalification Stakeholders Meeting Geneva, CICG 4 and 5 April 2011 Dr. Nora Dellepiane
More information